NASDAQ:FOLD - Amicus Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.74 +0.18 (+1.09 %)
(As of 05/20/2018 11:22 AM ET)
Previous Close$16.74
Today's Range$16.45 - $16.9050
52-Week Range$7.46 - $17.40
Volume3.93 million shs
Average Volume2.57 million shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.48

About Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics logoAmicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Debt-to-Equity Ratio0.32
Current Ratio4.21
Quick Ratio4.15

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.93 million
Price / Sales85.43
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book6.04

Profitability

EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-563.98%
Return on Equity-60.09%
Return on Assets-29.90%

Miscellaneous

Employees325
Outstanding Shares188,470,000

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics (NASDAQ:FOLD) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.08. The biopharmaceutical company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. View Amicus Therapeutics' Earnings History.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Amicus Therapeutics.

What price target have analysts set for FOLD?

7 Wall Street analysts have issued twelve-month price targets for Amicus Therapeutics' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate Amicus Therapeutics' stock price to reach $19.50 in the next twelve months. View Analyst Ratings for Amicus Therapeutics.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 29,160,247 shares, an increase of 0.1% from the April 13th total of 29,121,592 shares. Based on an average daily volume of 1,954,527 shares, the days-to-cover ratio is presently 14.9 days. Approximately 15.9% of the company's stock are sold short.

Who are some of Amicus Therapeutics' key competitors?

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the folowing people:
  • Mr. John F. Crowley, Chairman and Chief Exec. Officer (Age 51)
  • Mr. Bradley L. Campbell, Pres and Chief Operating Officer (Age 42)
  • Mr. William D. Baird III, Chief Financial Officer (Age 46)
  • Dr. Hung Do Ph.D., Chief Science Officer (Age 50)
  • Dr. Jay A. Barth M.D., Chief Medical Officer (Age 54)

Has Amicus Therapeutics been receiving favorable news coverage?

Media coverage about FOLD stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amicus Therapeutics earned a coverage optimism score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Redmile Group LLC (5.70%), Palo Alto Investors LP (3.26%), Franklin Resources Inc. (2.00%), Farallon Capital Management LLC (1.85%) and Victory Capital Management Inc. (1.63%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Highland Capital Management LP, Royal Bank of Canada, Prudential Financial Inc., Copernicus Capital Management LLC, Candriam Luxembourg S.C.A., Seven Eight Capital LP and Russell Investments Group Ltd.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Sphera Funds Management LTD., Redmile Group LLC, Farallon Capital Management LLC, Victory Capital Management Inc., Loomis Sayles & Co. L P and Delek Group Ltd.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $16.74.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $3.16 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


MarketBeat Community Rating for Amicus Therapeutics (FOLD)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amicus Therapeutics (NASDAQ:FOLD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Amicus Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 16.49%. The high price target for FOLD is $24.00 and the low price target for FOLD is $15.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$19.50$19.50$18.0714
Price Target Upside: 16.49% upside17.75% upside17.75% upside13.09% upside

Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History

Price Target History for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018CowenReiterated RatingBuy$22.00MediumView Rating Details
2/8/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $24.00HighView Rating Details
2/7/2018Robert W. BairdSet Price TargetBuy$20.00HighView Rating Details
10/6/2017Goldman SachsReiterated RatingNeutral ➝ Neutral$17.00N/AView Rating Details
10/5/2017Chardan CapitalReiterated RatingBuy$16.50 ➝ $18.50N/AView Rating Details
10/4/2017JPMorgan ChaseReiterated RatingOverweightN/AView Rating Details
10/4/2017Bank of AmericaBoost Price TargetBuy$15.00 ➝ $20.00HighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Amicus Therapeutics (NASDAQ:FOLD) Earnings History and Estimates Chart

Earnings by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) Earnings Estimates

2018 EPS Consensus Estimate: ($1.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.33)($0.33)($0.33)
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.32)($0.32)($0.32)

Amicus Therapeutics (NASDAQ FOLD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.33)N/AView Earnings Details
5/8/2018Q1 2018($0.36)($0.28)$16.78 million$16.70 millionViewN/AView Earnings Details
2/28/2018Q4 2017($0.30)($0.41)$14.50 million$14.73 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.31)($0.41)$9.02 million$10.90 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.34)$6.96 million$7.16 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)$4.16 million$4.20 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.33)($0.32)$3.16 million$2.83 millionViewListenView Earnings Details
11/7/2016Q3($0.31)($0.33)$1.71 million$2.10 millionViewListenView Earnings Details
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4 2015($0.31)($0.35)ViewN/AView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.26)ViewN/AView Earnings Details
5/5/2015Q115($0.14)($0.25)$0.50 millionViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)$0.48 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.21)($0.22)$1.00 million$0.29 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.24)($0.23)$0.48 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.25)$0.20 million$0.46 millionViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)$0.32 millionViewN/AView Earnings Details
11/11/2013Q3($0.3220)($0.29)$0.04 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.36)($0.23)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.23)($0.20)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.34)($0.28)ViewN/AView Earnings Details
2/13/2012Q4 2011($0.37)$0.23ViewN/AView Earnings Details
11/1/2011Q3 2011($0.33)($0.38)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.32)($0.31)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.35)($0.29)ViewN/AView Earnings Details
2/14/2011Q4 2010($0.15)($0.45)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.49)($0.48)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.53)($0.41)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.57)($0.54)ViewN/AView Earnings Details
2/16/2010Q4 2009($0.59)$1.45ViewN/AView Earnings Details
10/29/2009Q3 2009($0.71)($0.59)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.63)($0.60)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.60)($0.55)ViewN/AView Earnings Details
2/5/2009Q4 2008($0.54)($0.63)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.44)($0.36)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.45)($0.41)ViewN/AView Earnings Details
5/13/2008Q1 2008($0.39)($0.35)ViewN/AView Earnings Details
1/29/2008Q4 2007($0.35)($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amicus Therapeutics (NASDAQ:FOLD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ FOLD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Hung DoInsiderSell25,000$15.00$375,000.00421,771View SEC Filing  
5/16/2018Margaret G McglynnDirectorSell10,000$16.00$160,000.0025,814View SEC Filing  
5/14/2018Jay BarthInsiderSell5,000$14.04$70,200.0090,409View SEC Filing  
4/17/2018Hung DoInsiderSell50,000$15.00$750,000.00446,771View SEC Filing  
4/16/2018Michael RaabDirectorSell5,000$14.41$72,050.0010,814View SEC Filing  
4/12/2018Jay BarthInsiderSell5,000$14.72$73,600.0090,409View SEC Filing  
4/2/2018Kurt J AndrewsSVPSell5,000$14.27$71,350.0045,469View SEC Filing  
4/2/2018William D Baird IIICFOSell10,000$14.26$142,600.00127,662View SEC Filing  
3/12/2018Jay BarthInsiderSell5,000$15.05$75,250.0090,409View SEC Filing  
3/9/2018Daphne QuimiSVPSell8,750$15.00$131,250.0073,082View SEC Filing  
3/5/2018Perceptive Advisors LlcMajor ShareholderBuy335,827$13.56$4,553,814.12View SEC Filing  
3/1/2018Daphne QuimiSVPSell8,149$14.06$114,574.9472,481View SEC Filing  
3/1/2018Life Sciences Maste PerceptiveMajor ShareholderBuy100,000$13.69$1,369,000.00View SEC Filing  
1/23/2018Jay BarthInsiderSell20,000$16.80$336,000.00105,409View SEC Filing  
1/22/2018Bradley L CampbellCOOSell32,500$15.92$517,400.00186,600View SEC Filing  
1/2/2018Daphne QuimiSVPSell8,000$14.72$117,760.0062,676View SEC Filing  
1/2/2018Donald J Hayden JrDirectorSell20,000$15.00$300,000.0025,814View SEC Filing  
1/2/2018Jay BarthInsiderSell5,000$14.71$73,550.0069,184View SEC Filing  
1/2/2018William D Baird IIICFOSell10,000$14.72$147,200.00105,121View SEC Filing  
12/29/2017John F CrowleyCEOSell18,970$14.75$279,807.50View SEC Filing  
12/29/2017John F CrowleyCEOSell5,920$14.75$87,320.00341,051View SEC Filing  
12/21/2017John F CrowleyCEOSell65,581$13.51$885,999.31393,076View SEC Filing  
12/11/2017John F CrowleyCEOSell12,206$13.52$165,025.12340,207View SEC Filing  
12/4/2017John F CrowleyCEOSell47,213$13.61$642,568.93375,214View SEC Filing  
12/1/2017Jay BarthInsiderSell5,000$13.59$67,950.0069,184View SEC Filing  
10/18/2017John F CrowleyCEOSell71,735$14.75$1,058,091.25380,723View SEC Filing  
10/16/2017John F CrowleyCEOSell449,295$14.33$6,438,397.35380,723View SEC Filing  
10/12/2017Daphne QuimiSVPSell7,000$14.25$99,750.00View SEC Filing  
10/12/2017Hung DoInsiderSell50,194$14.25$715,264.50View SEC Filing  
10/12/2017Michael RaabDirectorSell10,000$14.25$142,500.00View SEC Filing  
10/12/2017William D Baird IIICFOSell40,000$14.25$570,000.00View SEC Filing  
9/26/2017John F CrowleyCEOBuy1,395$14.36$20,032.20328,001View SEC Filing  
7/13/2017Life Sciences Maste PerceptiveMajor ShareholderBuy1,500,000$12.25$18,375,000.00View SEC Filing  
6/19/2017Jay BarthInsiderSell30,000$10.00$300,000.0064,184View SEC Filing  
5/19/2017Hung DoInsiderSell29,914$8.00$239,312.00474,438View SEC Filing  
3/2/2017Bradley L CampbellCOOSell49,050$8.00$392,400.00127,475View SEC Filing  
1/13/2017Hung DoInsiderSell25,000$6.00$150,000.00559,266View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$4.96$469,960.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy142,125$4.87$692,148.75View SEC Filing  
12/23/2016Perceptive Advisors LlcMajor ShareholderBuy85,275$4.81$410,172.75View SEC Filing  
12/22/2016Perceptive Advisors LlcMajor ShareholderBuy189,500$4.51$854,645.00View SEC Filing  
11/9/2016Daphne QuimiSVPSell8,546$8.00$68,368.0024,189View SEC Filing  
11/1/2016Hung DoInsiderSell25,000$7.00$175,000.00533,453View SEC Filing  
10/3/2016Hung DoInsiderSell25,000$7.25$181,250.00558,453View SEC Filing  
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.0056,450View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00583,453View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.0015,000View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.0025,458View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.0010,000View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.003,187View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78156,575View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.0856,575View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00720,953View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.005,688View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amicus Therapeutics (NASDAQ FOLD) News Headlines

Source:
DateHeadline
Is Amicus On The Verge Of A Breakout?Is Amicus On The Verge Of A Breakout?
seekingalpha.com - May 20 at 8:26 AM
Amicus Therapeutics (FOLD) Upgraded to Strong-Buy by BidaskClubAmicus Therapeutics (FOLD) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - May 19 at 1:00 PM
Amicus Therapeutics (FOLD) Director Sells $160,000.00 in StockAmicus Therapeutics (FOLD) Director Sells $160,000.00 in Stock
www.americanbankingnews.com - May 18 at 8:32 PM
Interesting FOLD Put And Call Options For September 21stInteresting FOLD Put And Call Options For September 21st
www.nasdaq.com - May 18 at 5:42 PM
$18.92 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter$18.92 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter
www.americanbankingnews.com - May 18 at 2:18 AM
Insider Selling: Amicus Therapeutics (FOLD) Insider Sells 25,000 Shares of StockInsider Selling: Amicus Therapeutics (FOLD) Insider Sells 25,000 Shares of Stock
www.americanbankingnews.com - May 16 at 7:50 PM
Amicus Therapeutics (FOLD) Expected to Post Earnings of -$0.33 Per ShareAmicus Therapeutics (FOLD) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - May 16 at 5:16 PM
Amicus Therapeutics (FOLD) Insider Sells $70,200.00 in StockAmicus Therapeutics (FOLD) Insider Sells $70,200.00 in Stock
www.americanbankingnews.com - May 15 at 10:10 PM
Edited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 12 at 8:00 AM
Amicus Therapeutics (FOLD) Rating Increased to Hold at Zacks Investment ResearchAmicus Therapeutics (FOLD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 10 at 10:52 PM
Leerink Swann Equities Analysts Raise Earnings Estimates for Amicus Therapeutics (FOLD)Leerink Swann Equities Analysts Raise Earnings Estimates for Amicus Therapeutics (FOLD)
www.americanbankingnews.com - May 10 at 6:54 AM
Amicus Therapeutics (FOLD) Given Average Recommendation of "Buy" by AnalystsAmicus Therapeutics (FOLD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 3:32 AM
Amicus Therapeutics (FOLD) Announces  Earnings Results, Beats Expectations By $0.08 EPSAmicus Therapeutics (FOLD) Announces Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 8:34 PM
Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care ConferenceAmicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 8:12 AM
Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)
www.americanbankingnews.com - May 9 at 6:49 AM
Amicus Therapeutics down 3% on Q1 resultsAmicus Therapeutics down 3% on Q1 results
seekingalpha.com - May 8 at 5:46 PM
Amicus Therapeutics (FOLD) CEO John Crowley on Q1 2018 Results - Earnings Call TranscriptAmicus Therapeutics' (FOLD) CEO John Crowley on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:46 PM
When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)?When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)?
finance.yahoo.com - May 8 at 5:46 PM
Amicus Therapeutics: 1Q Earnings SnapshotAmicus Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:46 PM
Amicus Therapeutics (FOLD) "Buy" Rating Reaffirmed at CowenAmicus Therapeutics' (FOLD) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 8 at 4:40 PM
Amicus Therapeutics beats by $0.08, misses on revenueAmicus Therapeutics beats by $0.08, misses on revenue
seekingalpha.com - May 8 at 8:12 AM
Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate UpdatesAmicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
finance.yahoo.com - May 8 at 8:12 AM
Amicus Therapeutics (FOLD) Upgraded to Buy by BidaskClubAmicus Therapeutics (FOLD) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - May 5 at 12:12 AM
ValuEngine Upgrades Amicus Therapeutics (FOLD) to Strong-BuyValuEngine Upgrades Amicus Therapeutics (FOLD) to Strong-Buy
www.americanbankingnews.com - May 4 at 12:52 AM
Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to SellZacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell
www.americanbankingnews.com - May 3 at 12:14 AM
Amicus Therapeutics (FOLD) Expected to Announce Quarterly Sales of $16.78 MillionAmicus Therapeutics (FOLD) Expected to Announce Quarterly Sales of $16.78 Million
www.americanbankingnews.com - May 1 at 4:12 AM
Analyzing the Market Potential for Amicus’s GalafoldAnalyzing the Market Potential for Amicus’s Galafold
finance.yahoo.com - April 30 at 5:29 PM
Exploring Amicus Therapeutics’ Promising Research PipelineExploring Amicus Therapeutics’ Promising Research Pipeline
finance.yahoo.com - April 30 at 5:29 PM
Analyzing the Financial Performance of Amicus TherapeuticsAnalyzing the Financial Performance of Amicus Therapeutics
finance.yahoo.com - April 30 at 5:29 PM
Amicus Therapeutics (FOLD) to Release Earnings on MondayAmicus Therapeutics (FOLD) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 7:49 AM
 Brokerages Anticipate Amicus Therapeutics (FOLD) to Post -$0.36 Earnings Per Share Brokerages Anticipate Amicus Therapeutics (FOLD) to Post -$0.36 Earnings Per Share
www.americanbankingnews.com - April 29 at 5:16 AM
Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
feeds.benzinga.com - April 26 at 7:57 AM
Traders Buy High Volume of Amicus Therapeutics Call Options (FOLD)Traders Buy High Volume of Amicus Therapeutics Call Options (FOLD)
www.americanbankingnews.com - April 25 at 7:36 AM
Amicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClubAmicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio PharmaTechnical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma
www.prnewswire.com - April 20 at 8:01 AM
Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock OptionsImplied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
www.zacks.com - April 20 at 8:01 AM
Amicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 SharesAmicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 Shares
www.americanbankingnews.com - April 19 at 7:34 PM
Amicus Therapeutics (FOLD) Director Sells $72,050.00 in StockAmicus Therapeutics (FOLD) Director Sells $72,050.00 in Stock
www.americanbankingnews.com - April 18 at 7:49 PM
Jay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) StockJay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) Stock
www.americanbankingnews.com - April 16 at 7:14 PM
Portfolio Review: Continued Market Outperformance In Q1 2018Portfolio Review: Continued Market Outperformance In Q1 2018
seekingalpha.com - April 15 at 8:43 AM
Amicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from AnalystsAmicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 3:25 AM
$16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter$16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter
www.americanbankingnews.com - April 14 at 4:39 AM
Amicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClubAmicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM
Amicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClubAmicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 11:05 AM
Zacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per ShareZacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 12 at 5:23 AM
Amicus Therapeutics Sees Unusually High Options Volume (FOLD)Amicus Therapeutics Sees Unusually High Options Volume (FOLD)
www.americanbankingnews.com - April 11 at 7:06 AM
Amicus Therapeutics (FOLD) PT Raised to $17.50Amicus Therapeutics (FOLD) PT Raised to $17.50
www.americanbankingnews.com - April 10 at 11:38 PM
Amicus Therapeutics (FOLD) Upgraded at Zacks Investment ResearchAmicus Therapeutics (FOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM
Amicus Therapeutics (FOLD) SVP Sells $71,350.00 in StockAmicus Therapeutics (FOLD) SVP Sells $71,350.00 in Stock
www.americanbankingnews.com - April 4 at 11:18 PM
William D. Baird III Sells 10,000 Shares of Amicus Therapeutics (FOLD) StockWilliam D. Baird III Sells 10,000 Shares of Amicus Therapeutics (FOLD) Stock
www.americanbankingnews.com - April 4 at 11:17 PM

SEC Filings

Amicus Therapeutics (NASDAQ:FOLD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.